Antimicrobial Resistance in Cancer Care: Challenge and Path Forward

ABSTRACT Introduction Antimicrobial resistance (AMR) is a global health crisis that poses a devastating and specific threat to immunocompromised cancer patients, who are heavily reliant on antibiotics to navigate high‐risk treatments. The rapid emergence of multidrug‐resistant (MDR) pathogens compromises the efficacy of prophylaxis and empirical therapy, leading to increased morbidity, mortality, and economic burden. This article aims to critically analyze the unique challenges of AMR in oncology and evaluate the translational readiness of innovative therapeutic modalities as a sustainable path forward. Methods We synthesize current literature to articulate the clinical and economic burden of AMR specifically within the oncology setting. The article goes beyond conventional antibiotic stewardship discussions to critically appraise non‐traditional strategies, including the clinical and regulatory barriers facing bacteriophage therapy, antimicrobial peptides (AMPs), and CRISPR‐Cas systems. Results AMR threatens the safe delivery of systemic cancer therapies, as resistant infections necessitate dose modifications and treatment delays. Traditional antibiotic development is insufficient. The path forward requires a paradigm shift: coupling robust stewardship and rapid diagnostics with a critical investment in innovative therapies. While promising, these novel modalities are not “silver bullets” and face significant hurdles in standardization, manufacturing, and regulatory approval that must be addressed for clinical integration into cancer care. Conclusion The fight against AMR is inseparable from the fight against cancer. To safeguard the future of oncology, a concerted effort is required to advance non‐traditional anti‐infectives through the translational pipeline, while ensuring immediate, tailored infection management for this vulnerable population.